BDBM359626 N-({2,4-Dimethyl-7H-pyrrolo[2,3-b]pyridin-3-yl}methyl)-5-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)pyridine-3-carboxamide::US10221161, Example 12
SMILES: Cc1cnn(Cc2ccc(Cc3cncc(c3)C(=O)NCc3c(C)nc4[nH]ccc(C)c34)cc2)c1
InChI Key: InChIKey=ZBVFUONSGPAIOP-UHFFFAOYSA-N
Data: 2 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kallikrein 1 (Homo sapiens (Human)) | BDBM359626 (N-({2,4-Dimethyl-7H-pyrrolo[2,3-b]pyridin-3-yl}met...) | PDB UniProtKB/SwissProt UniProtKB/TrEMBL antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.49E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Kalvista Pharmaceuticals Limited US Patent | Assay Description KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ... | US Patent US10221161 (2019) BindingDB Entry DOI: 10.7270/Q23B62DG | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM359626 (N-({2,4-Dimethyl-7H-pyrrolo[2,3-b]pyridin-3-yl}met...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 244 | n/a | n/a | n/a | n/a | n/a | n/a |
Kalvista Pharmaceuticals Limited US Patent | Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8... | US Patent US10221161 (2019) BindingDB Entry DOI: 10.7270/Q23B62DG | |||||||||||
More data for this Ligand-Target Pair |